Vlad Ratziu

List of Publications by Year
in descending order

186	21,204	26630 56	10445 139
papers	citations	h-index	g-index

192	192	192	15208
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. Gastroenterology, 2023, 165, 5-10.	1.3	59
2	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2023, 21, 713-722.e3.	4.4	9
3	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 2050-2058.e12.	4.4	41
4	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. Journal of Hepatology, 2022, 76, 265-274.	3.7	24
5	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
6	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology, 2022, 76, 506-517.	3.7	49
7	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology, 2022, 76, 536-548.	3.7	66
8	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. Gastroenterology, 2022, 162, 680-688.	1.3	53
9	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	4.9	20
10	From the Editorâ€™s Desk.... Journal of Hepatology, 2022, 76, 1-4.	3.7	0
11	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	3.7	74
12	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology, 2022, 76, 456-468.	7.3	22
13	From the Editorâ€™s Desk.... Journal of Hepatology, 2022, 76, 257-260.	3.7	0
14	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	3.7	54
15	Reply. Hepatology, 2022, 76, E43-E43.	7.3	0
16	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Biomedicines, 2022, 10, 699.	3.2	7
17	From the Editorâ€™s Desk.... Journal of Hepatology, 2022, 76, 491-494.	3.7	0
18	Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. Hepatology, 2022, 76, 1360-1375.	7.3	30

#	Article	IF	Citations
19	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	3.7	114
20	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15
21	An international survey on patterns of practice in NAFLD and expectations for therapiesâ€"The POPâ€NEXT project. Hepatology, 2022, 76, 1766-1777.	7.3	7
22	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2022, 76, 759-762.	3.7	0
23	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100477.	4.9	31
24	Reply. Hepatology, 2022, 76, E53-E53.	7.3	0
25	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2022, 76, 991-994.	3.7	0
26	Breakthroughs in therapies for NASH and remaining challenges. Journal of Hepatology, 2022, 76, 1263-1278.	3.7	66
27	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
28	Real-World Burden of Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1020-1029.e7.	4.4	21
29	From the Editor's Deskâ€¦. Journal of Hepatology, 2021, 74, 265-268.	3.7	0
30	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2021, 384, 1113-1124.	27.0	833
31	From the Editor's Deskâ€¦. Journal of Hepatology, 2021, 74, 1-4.	3.7	4
32	Liver Stiffness by Transient Elastography to Detect Portoâ€Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74, 364-378.	7.3	40
33	Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). Microorganisms, 2021, 9, 199.	3.6	33
34	coreNASH: Multiâ€stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatology Communications, 2021, 5, 774-785.	4.3	3
35	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	27.8	649
36	From the Editor's Deskâ€¦. Journal of Hepatology, 2021, 74, 493-496.	3.7	0

#	Article	IF	Citations
37	Disease burden and economic impact of diagnosed nonâ€alcoholic steatohepatitis in five European countries in 2018: A costâ€ofâ€illness analysis. Liver International, 2021, 41, 1227-1242.	3.9	76
38	Yet more evidence that MAFLD is more than a name change. Journal of Hepatology, 2021, 74, 977-979.	3.7	25
39	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 765-768.	3.7	0
40	European â€˜NAFLD Preparedness Indexâ€™ â€" Is Europe ready to meet the challenge of fatty liver disease?. JHEP Reports, 2021, 3, 100234.	4.9	27
41	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 1005-1008.	3.7	0
42	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2021, 17, 398-400.	2.1	2
43	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2021, 74, 1277-1280.	3.7	0
44	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology, 2021, 161, 1475-1486.	1.3	101
45	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 75, 1-4.	3.7	3
46	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. JHEP Reports, 2021, 3, 100298.	4.9	6
47	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. Journal of Hepatology, 2021, 75, 1292-1300.	3.7	27
48	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2021, 75, 257-260.	3.7	1
49	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. The Lancet Gastroenterology and Hepatology, 2021, 6, 889-902.	8.1	26
50	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2021, 75, 499-502.	3.7	0
51	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2021, 75, 757-760.	3.7	3
52	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	3.7	149
53	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Science Translational Medicine, 2021, 13, eabe8939.	12.4	17
54	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. New England Journal of Medicine, 2021, 385, 1547-1558.	27.0	284

#	Article	IF	Citations
55	From the Editorâ€™s deskâ€¦. Journal of Hepatology, 2021, 75, 1013-1016.	3.7	0
56	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut, 2021, 70, 2359-2372.	12.1	56
57	From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 75, 1261-1264.	3.7	0
58	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Frontiers in Nutrition, 2021, 8, 774030.	3.7	20
59	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. Journal of Hepatology, 2020, 72, 14-24.	3.7	123
60	Development and Validation of Hepamet Fibrosis Scoring Systemâ€“A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. Clinical Gastroenterology and Hepatology, 2020, 18, 216-225.e5.	4.4	104
61	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. Contemporary Clinical Trials, 2020, 88, 105889.	1.8	80
62	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 72, 828-838.	3.7	52
63	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. European Journal of Gastroenterology and Hepatology, 2020, 32, 998-1007.	1.6	8
64	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. Journal of Hepatology, 2020, 72, 627-635.	3.7	84
65	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. Molecular Genetics and Metabolism, 2020, 129, 59-66.	1.1	17
66	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemporary Clinical Trials, 2020, 97, 106174.	1.8	25
67	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. Contemporary Clinical Trials, 2020, 98, 106175.	1.8	71
68	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 73, 1001-1004.	3.7	0
69	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 73, 475-478.	3.7	0
70	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine, 2020, 12, .	12.4	205
71	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology and Hepatology, 2020, 5, 970-985.	8.1	142
72	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Reports, 2020, 2, 100142.	4.9	53

#	Article	IF	Citations
73	From the Editor's Desk.... Journal of Hepatology, 2020, 73, 745-748.	3.7	0
74	Clinical endpoints are necessary in the interim analysis of REGENERATE â€“ Authors' reply. Lancet, The, 2020, 396, 663-664.	13.7	0
75	The times they are a-changin' (for NAFLD as well). Journal of Hepatology, 2020, 73, 1307-1309.	3.7	45
76	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Advances in Therapy, 2020, 37, 4627-4640.	2.9	4
77	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. Medical Decision Making, 2020, 40, 830-845.	2.4	8
78	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 73, 1299-1302.	3.7	0
79	Introducing the Expert Opinion series. Journal of Hepatology, 2020, 73, 5.	3.7	4
80	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 72, 1039-1042.	3.7	0
81	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. Nature Metabolism, 2020, 2, 514-531.	11.9	31
82	From the Editor's Desk.... Journal of Hepatology, 2020, 72, 597-600.	3.7	0
83	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. Scientific Reports, 2020, 10, 3850.	3.3	39
84	From the Editor's Desk.... Journal of Hepatology, 2020, 73, 1-4.	3.7	3
85	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 73, 227-230.	3.7	0
86	Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. Hepatology, 2020, 71, 1146-1149.	7.3	0
87	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
88	From the Editor's Deskâ€¦. Journal of Hepatology, 2020, 72, 379-383.	3.7	0
89	Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology, 2020, 72, 892-905.	7.3	227
90	Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology, 2020, 159, 422-427.e1.	1.3	15

#	Article	IF	Citations
91	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	3.7	2,171
92	From the Editorâ€™s Deskâ€¦. Journal of Hepatology, 2020, 72, 805-808.	3.7	0
93	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	3.7	279
94	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. Cell Reports Medicine, 2020, 1, 100154.	6.5	23
95	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	2.5	10
96	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 235-245.	0.9	11
97	Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. Journal of Gastrointestinal and Liver Diseases, 2020, 25, 183-189.	0.9	5
98	Relationship Among Fatty Liver, Specific and Multipleâ€Site Atherosclerosis, and 10â€Year Framingham Score. Hepatology, 2019, 69, 1453-1463.	7.3	41
99	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemporary Clinical Trials, 2019, 84, 105803.	1.8	105
100	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacology and Therapeutics, 2019, 50, 193-203.	3.7	112
101	Editorial: it is not a wideâ€open field for incretins â€•collateral benefits favour the use of metformin in advanced nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 611-612.	3.7	0
102	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. JHEP Reports, 2019, 1, 188-198.	4.9	86
103	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation, 2019, 103, 28-38.	1.0	28
104	External validation of an algorithm combining multiâ€analyte blood tests (FibroTestâ€ŁCR1â€ŁCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. GastroHep, 2019, 1, 146-153.	0.6	3
105	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology, 2019, 70, 1841-1855.	7.3	64
106	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology, 2019, 70, 1913-1927.	7.3	226
107	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 454-465.	8.1	36
108	Improving NASH with a little help from thyromimetics. Lancet, The, 2019, 394, 1970-1972.	13.7	4

#	Article	IF	Citations
109	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
110	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. European Journal of Gastroenterology and Hepatology, 2019, 31, 393-402.	1.6	12
111	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e86-e94.	2.1	53
112	LCR1 and LCR2, two multiâ€analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 308-320.	3.7	15
113	Rates of and Factors Associated With Placebo Response inÂTrials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 616-629.e26.	4.4	91
114	Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 416-426.	1.5	12
115	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. European Journal of Gastroenterology and Hepatology, 2018, 30, 569-577.	1.6	15
116	Impact of steatosis and inflammation definitions on the performance of NASH tests. European Journal of Gastroenterology and Hepatology, 2018, 30, 384-391.	1.6	13
117	The painful reality of end-stage liver disease in NASH. The Lancet Gastroenterology and Hepatology, 2018, 3, 8-10.	8.1	8
118	NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 415-417.e1.	4.5	0
119	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). American Journal of Gastroenterology, 2018, 113, 443-445.	0.4	2
120	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
121	A randomized, placeboâ€controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology, 2018, 67, 1754-1767.	7.3	528
122	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. Journal of Hepatology, 2018, 68, 353-361.	3.7	58
123	NAFLD: The evolving landscape. Journal of Hepatology, 2018, 68, 227-229.	3.7	11
124	Longâ€term prognostic value of the FibroTest in patients with nonâ€alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1117-1127.	3.7	28
125	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. Gastroenterology, 2018, 155, 1140-1153.	1.3	253
126	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. Journal of Hepatology, 2018, 69, 1365-1370.	3.7	51

#	Article	IF	Citations
127	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
128	Nonâ€pharmacological interventions in nonâ€alcoholic fatty liver disease patients. Liver International, 2017, 37, 90-96.	3.9	34
129	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. Gut, 2017, 66, 1688-1696.	12.1	59
130	Screening studies of transient elastography and FibroTest in the general population. The Lancet Gastroenterology and Hepatology, 2017, 2, 246.	8.1	1
131	Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology, 2017, 67, 1134-1136.	3.7	16
132	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. American Journal of Gastroenterology, 2017, 112, 740-751.	0.4	524
133	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS ONE, 2017, 12, e0189436.	2.5	13
134	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 428-432.	1.3	19
135	Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, G942-G944.	3.4	3
136	Novel Pharmacotherapy Options for NASH. Digestive Diseases and Sciences, 2016, 61, 1398-1405.	2.3	35
137	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. Contemporary Clinical Trials, 2016, 47, 356-365.	1.8	178
138	Fatty liver is an independent predictor of early carotid atherosclerosis. Journal of Hepatology, 2016, 65, 95-102.	3.7	91
139	NAFLD and liver transplantation: Current burden and expected challenges. Journal of Hepatology, 2016, 65, 1245-1257.	3.7	352
140	Reply to â€œEstablishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular diseaseâ€. Journal of Hepatology, 2016, 65, 1267-1268.	3.7	2
141	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 2016, 3, e000075.	2.7	90
142	When the journey from obesity to cirrhosis takes an early start. Journal of Hepatology, 2016, 65, 249-251.	3.7	8
143	Elafibranor, an Agonist of the Peroxisome Proliferatorâ^'Activated Receptorâ^'Î± andÂâ^'Î´, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	1.3	847
144	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. PLoS ONE, 2016, 11, e0163276.	2.5	26

#	Article	IF	Citations
145	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. BMJ Open, 2015, 5, e010017.	1.9	9
146	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. European Journal of Internal Medicine, 2015, 26, 30-36.	2.2	42
147	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology, 2015, 61, 1041-1055.	7.3	102
148	Non-alcoholic fatty liver â€“ Perhaps not so benign. Journal of Hepatology, 2015, 62, 1002-1004.	3.7	38
149	Current efforts and trends in the treatment of NASH. Journal of Hepatology, 2015, 62, S65-S75.	3.7	228
150	Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. Clinical Gastroenterology and Hepatology, 2015, 13, 763-771.e6.	4.4	65
151	Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. Clinical Gastroenterology and Hepatology, 2015, 13, 992-999.e2.	4.4	26
152	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infectious Diseases, The, 2015, 15, 397-404.	9.1	267
153	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. Future Oncology, 2015, 11, 2553-2562.	2.4	13
154	Starting the battle to control non-alcoholic steatohepatitis. Lancet, The, 2015, 385, 922-924.	13.7	14
155	Concordance of sustained virological response 4, 12, and 24 weeks postâ€treatment with sofosbuvirâ€containing regimens for hepatitis C virus. Hepatology, 2015, 61, 41-45.	7.3	173
156	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. PLoS ONE, 2015, 10, e0134302.	2.5	14
157	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World Journal of Gastroenterology, 2015, 21, 5647.	3.3	13
158	Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. Digestive Diseases, 2014, 32, 586-596.	1.9	10
159	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon Î±-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 3429-3436.	3.2	13
160	Hepatic molecular effects of rosiglitazone in human nonâ€alcoholic steatohepatitis suggest longâ€term proâ€inflammatory damage. Hepatology Research, 2014, 44, 1241-1247.	3.4	16
161	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTestâ„¢) and transient elastography (FibroScanÂ®). Journal of Hepatology, 2014, 60, 706-714.	3.7	101
162	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Journal of Hepatology, 2014, 61, 1220-1227.	3.7	25

#	Article	IF	Citations
163	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTestÂ®) and elastography (FibroScanÂ®). Journal of Hepatology, 2014, 61, 994-1003.	3.7	42
164	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications, 2014, 5, 4309.	12.8	478
165	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. Clinics in Liver Disease, 2014, 18, 165-178.	2.1	34
166	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: â€œAPRI câ€™est finiÂ?â€• Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 432-439.	1.5	10
167	Targeting non-alcoholic fatty liver disease through 11-Î²HSD1 inhibition. Lancet Diabetes and Endocrinology,the, 2014, 2, 354-356.	11.4	4
168	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2013, 58, 1941-1952.	7.3	355
169	Pharmacological agents for NASH. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 676-685.	17.8	58
170	Pharmacological agents for nonalcoholic steatohepatitis. Hepatology International, 2013, 7, 833-841.	4.2	2
171	Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. Journal of Infectious Diseases, 2013, 208, 1000-1007.	4.0	27
172	From NAFLD in clinical practice to answers from guidelines. Journal of Hepatology, 2013, 59, 859-871.	3.7	304
173	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology, 2013, 59, 550-556.	3.7	421
174	Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. Journal of Clinical Virology, 2013, 58, 385-390.	3.1	10
175	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. Journal of Hepatology, 2013, 59, 675-683.	3.7	134
176	Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. Journal of Hepatology, 2013, 58, 928-935.	3.7	151
177	Is mipomersen ready for clinical implementation? A transatlantic dilemma. Current Opinion in Lipidology, 2013, 24, 301-306.	2.7	19
178	Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Annals of Internal Medicine, 2013, 159, 370.	3.9	2
179	Randomized Study of Asunaprevir plus Pegylated Interferon-Î± and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. Antiviral Therapy, 2013, 18, 885-893.	1.0	44
180	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World Journal of Gastroenterology, 2013, 19, 57.	3.3	104

#	Article	IF	Citations
181	Treatment of NASH with ursodeoxycholic acid: Pro. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, S41-S45.	1.5	28
182	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. Journal of Hepatology, 2012, 57, 541-548.	3.7	65
183	Performances of Elasto-FibroTestÂ®, a combination between FibroTestÂ® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 455-463.	1.5	16
184	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. BMC Gastroenterology, 2011, 11, 39.	2.0	58
185	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology, 2006, 6, 6.	2.0	378
186	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet, The, 2001, 357, 1069-1075.	13.7	1,316